Last reviewed · How we verify

SFP

Rockwell Medical Technologies, Inc. · FDA-approved active Small molecule

SFP is an iron-based intravenous therapy that replenishes iron stores and stimulates erythropoiesis in patients with iron deficiency anemia.

SFP is an iron-based intravenous therapy that replenishes iron stores and stimulates erythropoiesis in patients with iron deficiency anemia. Used for Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or unresponsive to oral iron.

At a glance

Generic nameSFP
Also known asSoluble ferric pyrophosphate
SponsorRockwell Medical Technologies, Inc.
Drug classIntravenous iron replacement agent
TargetIron (Fe3+) for hemoglobin synthesis and erythropoiesis
ModalitySmall molecule
Therapeutic areaHematology / Nephrology
PhaseFDA-approved

Mechanism of action

SFP (likely referring to a ferric or iron-based formulation from Rockwell Medical) delivers bioavailable iron intravenously to correct iron deficiency and support red blood cell production. It is designed for patients who cannot tolerate or do not respond adequately to oral iron supplementation, particularly those with chronic kidney disease or other conditions causing iron-deficient anemia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: